

First author	Country (year)	Baseline (Experience group)	Baseline (Control group)	Types of DPP-4 inhibitors	Control measures	Duration
(A)		CIMT(mm)	CIMT(mm)			
Shinji Ishikawa[20]	(Japan) 2014	1.11±0.43	1.02±0.44	Sitagliptin	Placebo	12 months
Tomoya Mita[19]	(Japan) 2016b	0.83±0.15	0.83±0.17	Alogliptin	Conventional	24 months
Tomoya Mita[21]	(Japan) 2016a	0.84±0.19	0.84±0.21	Sitagliptin	Conventional	24 months
Jun-ichi Oyama[22]	(Japan) 2016	0.83±0.17	0.84±0.190	Sitagliptin	Conventional	24 months
Murakami T.[23]	(Japan) 2018	1.11±0.38	1.09±0.45	Linagliptin	Conventional	24 months
Murakami T.[24]	(Japan) 2015	1.10±0.35	1.09±0.46	Sitagliptin	Conventional	24 months
(B)		FMD(%)	FMD(%)			
Dimitrios Baltzis[25]	United States (2016)	6.51±2.05	7.07±1.20	Linagliptin	Placebo	12 weeks
Gyuri Kim[26]	Korea (2017)	9.35±4.98	10.12±5.69	Vildagliptin	Glimepiride	12 weeks
Fang Li[27]	China (2017)	9.3±4.7	9.2±9.0	Saxagliptin	Metformin	12 weeks
murakami.T[28]	Japan (2013)	4.0±1.9	4.1±2.0	Sitagliptin	Conventional	104 weeks
murakami.T[23]	Japan (2018)	3.8±1.6	4.0±2.0	Linagliptin	Conventional	104 weeks
Kazufumi Nakamura[16]	Japan (2014)	5.41±2.25	4.96±2.16	Sitagliptin	Voglibose	12 weeks
Hiroshi Nomoto[29]	Japan (2016)	5.6±2.8	5.6±2.2	Sitagliptin	Glimepiride	26 weeks
Norbert J. Tripolt[30]	Austria (2018)	3.5±3.1	4.0±2.9	Linagliptin	Placebo	12 weeks
Tatsuya Maruhashi[31]	Japan (2016)	4.3±2.6	4.3±2.4	Sitagliptin	Conventional	104 weeks

Shigiyama[32]	Japan (2016)	4.93±2.71	5.5±2.42	Linagliptin	Metformin	16 weeks
Kitao[33]	Japan (2017)	5.48±2.03	6.14±2.99	Vildagliptin	Metformin	12 weeks
Widlansky[34]	United States (2017)	5.6±2.3	5.2±1.8	Sitagliptin	Placebo	8 weeks
Suzuki 2012[35]	Japan (2012)	3.67±2.30	3.35±1.93	Sitagliptin	Conventional	12 weeks
(C)		PWV(m/s)	PWV(m/s)			
Cosenso Martin[36]	Brazil (2018)	8.6±1.2	8.5±1.3	Vildagliptin	Glibenclamide	12 weeks
de Boer[41]	Netherlands (2017)	8.7±1.5	8.8±1.1	Linagliptin	Placebo	26 weeks
Scalzo[37]	United States (2019)	11.6±1.1	10.3±0.9	Sitagliptin	Glimepiride OR Placebo	12 weeks
Awal[10]	United States (2020)	10.8±2.8	14.2±4.3	Linagliptin	Placebo	12 weeks
Tomiyama 2016[38]	Japan (2016)	17.1±5.6	17.5±8.4	Sitagliptin	Metformin	104 weeks
Efstathiou, S. 2018[40]	Greece (2018)	NR	NR	Sitagliptin	SGLT-2 inhibitor and Metformin	24 weeks
Efstathiou, S. 2015[39]	Greece (2015)	NR	NR	Saxagliptin	SGLT-2 inhibitor and Metformin	24 weeks
Nedogoda 2020[42]	Russia (2020)	11.4±2.4	11.8±1.9	Sitagliptin	SGLT-2 inhibitor and Metformin	24 weeks
Zografou[43]	Greece (2015)	8.6±2.1	8.9±2	Vildagliptin	Metformin	24 weeks